U.S. markets open in 3 hours 34 minutes
  • S&P Futures

    3,436.50
    +4.25 (+0.12%)
     
  • Dow Futures

    28,200.00
    +18.00 (+0.06%)
     
  • Nasdaq Futures

    11,672.50
    +11.75 (+0.10%)
     
  • Russell 2000 Futures

    1,617.70
    +2.90 (+0.18%)
     
  • Crude Oil

    41.11
    -0.59 (-1.41%)
     
  • Gold

    1,920.70
    +5.30 (+0.28%)
     
  • Silver

    25.12
    +0.15 (+0.58%)
     
  • EUR/USD

    1.1851
    +0.0022 (+0.19%)
     
  • 10-Yr Bond

    0.7970
    0.0000 (0.00%)
     
  • Vix

    29.89
    +0.71 (+2.43%)
     
  • GBP/USD

    1.3056
    +0.0109 (+0.84%)
     
  • USD/JPY

    104.8930
    -0.5770 (-0.55%)
     
  • BTC-USD

    12,189.34
    +1,132.33 (+10.24%)
     
  • CMC Crypto 200

    245.05
    +6.13 (+2.57%)
     
  • FTSE 100

    5,823.28
    -65.94 (-1.12%)
     
  • Nikkei 225

    23,639.46
    +72.42 (+0.31%)
     

Hoth Therapeutics Announces its HT-003 Shows Positive Initial Data Inhibiting Toll-like Receptor 2 (TLR2)

·5 mins read

Initial data reports one of the most critical genes for acne pathophysiology, toll-like receptor 2 (TLR2), is significantly inhibited by HT-003

NEW YORK, Sept. 24, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced completing testing to examine the ability of HT-003 to block acne pathogenic gene expression in human keratinocytes, the major cell type of the epidermis and the outermost of the layers of the skin.

(PRNewsfoto/Hoth Therapeutics Inc.)
(PRNewsfoto/Hoth Therapeutics Inc.)

Dr. Jonathan Zippin, M.D., Ph.D., FAAD, Associate Professor of Dermatology at Weill Cornell Medicine and Hoth Senior Scientific Advisor, led the first phase of the study. "Thanks to Dr. Zippin and his team, we have gained insight and gathered significant data with regards to the significance of HT-003 in blocking acne pathogenic gene expression," stated Robb Knie, CEO of Hoth Therapeutics. "We will continue to monitor the data at lower doses and move onto the testing of rodent skin and carcinogenesis."

Initial data from the first phase of the research reports that one of the most critical genes for acne pathophysiology, toll-like receptor 2 (TLR2), is significantly inhibited by HT-003. In addition, HT-003 at doses as high as 50 µM led to no observable toxicity. During the next phase of the research, Dr. Zippin will identify the minimal effective dose required to block TLR2 signaling in response to a broad range of bacteria derived agonists to further elucidate the pathway.

"The ability of HT-003 to potently inhibit TLR2 expression suggests that this drug will not only be effective for acne but may also help a broad range of patients suffering from disease driven by over active inflammatory responses to bacteria," stated Dr. Zippin.

Once HT-003 biomarkers have been identified using thein vitro human keratinocytes models, testing will move onto into live rodents.

About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit https://ir.hoththerapeutics.com/.

Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-its-ht-003-shows-positive-initial-data-inhibiting-toll-like-receptor-2-tlr2-301137358.html

SOURCE Hoth Therapeutics, Inc.